Gemcitabine Sensitivity Factors, hENT1 and RRM1 as Potential Prognostic Biomarker for Advanced Biliary Tract Cancer
(0) Objective: To determine whether hENT1 and RRM1 could be used as the biomarkers to assess the efficacy of chemotherapy and predict survival in patients with advanced biliary tract caner (BTC).Methods: The analysis was performed on samples collected from 44 patients with unresectable or recurrent BTC who were treated with gemcitabine as first-line therapy.We determined the levels of hENT1 and RRM1 with immunohistochemistry (IHC).Also, its prognostic and predictive role on tumor response and several clinical factors for survival were evaluated with Kaplan-Meier or Cox analysis.Results: The patients who were clinically benefited had significantly higher level of hENT1 (P =0.046) and lower level of RRM1 (P =0.033).Moreover, hENT1 expression was significantly Correlated with progression free survival (PFS) (P =0.005) and overall survival (OS) (P =0.048) in Cox univariate analysis.Also, hENT1 was an independent prognostic factor of OS (P =0.005).Conclusions: The expressions of hENT1 and RRM1 are associated with gemcitabine efficacy.hENT1 can be a reliable predictive marker of survival in patients with advanced BTC patients.
邓婷 潘虹 韩如冰 黄鼎智 李鸿立 巴一
天津医科大学附属肿瘤医院消化肿瘤内科
国内会议
第八届中国肿瘤内科大会、第三届中国肿瘤医师大会暨中国抗癌协会肿瘤临床化疗专业委员会2014年学术年会
北京
英文
564-565
2014-07-02（万方平台首次上网日期，不代表论文的发表时间）